Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the Sirt1/AMPK signaling pathway.

[1]  C. Xie,et al.  Mechanisms of Kaempferol in the treatment of diabetes: A comprehensive and latest review , 2022, Frontiers in Endocrinology.

[2]  Xiao Ma,et al.  Old wine in new bottles: kaempferol is a promising agent for treating the trilogy of liver diseases. , 2021, Pharmacological research.

[3]  M. Trauner,et al.  Novel therapeutic targets for cholestatic and fatty liver disease , 2021, Gut.

[4]  N. Hu,et al.  Kaempferol and Kaempferide Attenuate Oleic Acid-Induced Lipid Accumulation and Oxidative Stress in HepG2 Cells , 2021, International journal of molecular sciences.

[5]  B. Finck,et al.  Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus , 2021, Nature Reviews Endocrinology.

[6]  K. Zieniewicz,et al.  Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship , 2021, European journal of clinical investigation.

[7]  M. Roden,et al.  The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments , 2021, Nature Reviews Gastroenterology & Hepatology.

[8]  S. Friedman,et al.  Mechanisms and disease consequences of nonalcoholic fatty liver disease , 2021, Cell.

[9]  V. Wong,et al.  Non-alcoholic fatty liver disease , 2021, The Lancet.

[10]  N. AlFaris,et al.  Kaempferol suppresses acetaminophen-induced liver damage by upregulation/activation of SIRT1 , 2021, Pharmaceutical biology.

[11]  H. El‐Serag,et al.  Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention , 2020, Nature Reviews Gastroenterology & Hepatology.

[12]  J. Christianson,et al.  Reduced Liver-Specific PGC1a Increases Susceptibility for Short-Term Diet-Induced Weight Gain in Male Mice , 2020, bioRxiv.

[13]  W. März,et al.  Cholesterol Efflux Capacity and Cardiovascular Disease: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study , 2020, Biomedicines.

[14]  P. Malhotra,et al.  Disturbances in Cholesterol Homeostasis and Non-alcoholic Fatty Liver Diseases , 2020, Frontiers in Medicine.

[15]  Yongneng Zhang,et al.  p53‐Mediated Repression of the PGC1A (PPARG Coactivator 1α) and APLNR (Apelin Receptor) Signaling Pathways Limits Fatty Acid Oxidation Energetics: Implications for Cardio‐oncology , 2020, Journal of the American Heart Association.

[16]  R. Abbasalipourkabir,et al.  Fish oil and chicoric acid combination protects better against palmitate-induced lipid accumulation via regulating AMPK-mediated SREBP-1/FAS and PPARα/UCP2 pathways , 2020, Archives of physiology and biochemistry.

[17]  Tieqiao Wang,et al.  Preventive Effects of Kaempferol on High-Fat Diet-Induced Obesity Complications in C57BL/6 Mice , 2020, BioMed research international.

[18]  Yushui Ma,et al.  Hepatic Proteomic Changes and Sirt1/AMPK Signaling Activation by Oxymatrine Treatment in Rats With Non-alcoholic Steatosis , 2020, Frontiers in Pharmacology.

[19]  R. DeFronzo,et al.  GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH) , 2020, Expert opinion on investigational drugs.

[20]  C. Sirlin,et al.  Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. , 2019, The Journal of clinical investigation.

[21]  Yiming Lin,et al.  Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-κB signaling pathways , 2019, World journal of gastroenterology.

[22]  R. Carr,et al.  Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity , 2019, Current Obesity Reports.

[23]  Zhenzhou Jiang,et al.  Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice , 2019, Phytotherapy research : PTR.

[24]  Shuiping Zhao,et al.  miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease , 2019, Molecular Medicine.

[25]  M. Nourbakhsh,et al.  Hesperetin is a potent bioactivator that activates SIRT1-AMPK signaling pathway in HepG2 cells , 2019, Journal of Physiology and Biochemistry.

[26]  P. Muti,et al.  Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. , 2019, Cell metabolism.

[27]  S. Ghosh,et al.  Chronic consumption of fructose in combination with trans fatty acids but not with saturated fatty acids induces nonalcoholic steatohepatitis with fibrosis in rats , 2018, European Journal of Nutrition.

[28]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[29]  J. Lykkesfeldt,et al.  Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease , 2018, Cellular and Molecular Life Sciences.

[30]  R. Ke,et al.  Mechanisms of AMPK in the maintenance of ATP balance during energy metabolism , 2018, Cell biology international.

[31]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[32]  K. Kharbanda,et al.  Treatment options for alcoholic and non-alcoholic fatty liver disease: A review , 2017, World journal of gastroenterology.

[33]  Xiangmei Zhao,et al.  Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats , 2017, PloS one.

[34]  R. Ambrus,et al.  Physico-chemical and Biological Evaluation of Flavonols: Fisetin, Quercetin and Kaempferol Alone and Incorporated in beta Cyclodextrins. , 2017, Anti-cancer agents in medicinal chemistry.

[35]  B. Neuschwander‐Tetri.  Non-alcoholic fatty liver disease , 2017, BMC Medicine.

[36]  Jinghui Sun,et al.  Schisandra polysaccharide inhibits hepatic lipid accumulation by downregulating expression of SREBPs in NAFLD mice , 2016, Lipids in Health and Disease.

[37]  E. Tsochatzis,et al.  The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). , 2016, Metabolism: clinical and experimental.

[38]  G. Favero,et al.  Fructose Mediated Non-Alcoholic Fatty Liver Is Attenuated by HO-1-SIRT1 Module in Murine Hepatocytes and Mice Fed a High Fructose Diet , 2015, PloS one.

[39]  Liping Zhang,et al.  The anti-obesity and anti-diabetic effects of kaempferol glycosides from unripe soybean leaves in high-fat-diet mice. , 2015, Food & function.

[40]  Wei Zhu,et al.  Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice , 2014, Nutrition & Metabolism.

[41]  D. S̆timac,et al.  Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. , 2014, World journal of gastroenterology.

[42]  J. Browning,et al.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. , 2014, Gastroenterology.

[43]  S. Koo,et al.  Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis , 2013, Clinical and molecular hepatology.

[44]  Lingna Kong,et al.  Kaempferol suppresses lipid accumulation in macrophages through the downregulation of cluster of differentiation 36 and the upregulation of scavenger receptor class B type I and ATP-binding cassette transporters A1 and G1. , 2013, International journal of molecular medicine.

[45]  M. Jensen,et al.  Fat Depots, Free Fatty Acids, and Dyslipidemia , 2013, Nutrients.

[46]  T. Veenstra,et al.  SIRT1 Deacetylates and Inhibits SREBP-1C Activity in Regulation of Hepatic Lipid Metabolism* , 2010, The Journal of Biological Chemistry.

[47]  N. Ruderman,et al.  AMPK and SIRT1: a long-standing partnership? , 2010, American journal of physiology. Endocrinology and metabolism.

[48]  A. Hevener,et al.  AMPK β1 Deletion Reduces Appetite, Preventing Obesity and Hepatic Insulin Resistance* , 2009, The Journal of Biological Chemistry.

[49]  Hirokazu Takahashi,et al.  Dysfunctional very‐low‐density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis , 2009, Hepatology.

[50]  Robert V Farese,et al.  Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. , 2008, Journal of lipid research.

[51]  Philippe Giral,et al.  Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. , 2008, Gastroenterology.

[52]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[53]  G. Ronnett,et al.  Fatty Acid Metabolism, the Central Nervous System, and Feeding , 2006, Obesity.

[54]  P. Wilson,et al.  Estimation of very-low-density lipoprotein cholesterol from data on triglyceride concentration in plasma. , 1981, Clinical chemistry.